Tobira Therapeutics | Evaluate

Investors toast Galmed Nash results, but what will the FDA say?

Looking for value in the deal sweet spot

November 11, 2016

Snippet roundup: Christmas comes early for Pfizer’s bankers and Mannkind

October 28, 2016

Allergan buys Motus despite trial miss

October 17, 2016

M&A gives signs of reverting to the mean

September 21, 2016

Allergan’s second move spells showdown with Intercept and Gilead

September 20, 2016

Allergan sparks a second liver disease craze

July 25, 2016

Despite a deck stacked in its favour, Tobira fails in NASH

May 13, 2016

Upcoming events – NASH data from Tobira and Karyopharm’s myeloma trial

May 03, 2016

Therapy focus – NASH projects set for data in dog days of summer

September 24, 2015

Conatus makes a splash in NASH

Load More